SCC HOLDINGS BERHAD
KLSE (MYR): SCC (0158)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.23
Today's Change
0.00 (0.00%)
Day's Change
0.00 - 0.00
Trading Volume
0
Financial
Market Cap
Market Cap
32 Million
NOSH
141 Million
Latest Quarter
Latest Quarter
30-Sep-2024 [#3]
Announcement Date
22-Nov-2024
Next Quarter
31-Dec-2024
Est. Ann. Date
23-Feb-2025
Est. Ann. Due Date
01-Mar-2025
QoQ | YoY
-50.58% | 25.49%
T4Q Result
Revenue | NP to SH
54,721.000 | 1,431.000
RPS | P/RPS
38.77 Cent | 0.59
EPS | P/E | EY
1.01 Cent | 22.69 | 4.41%
DPS | DY | Payout %
0.00 Cent | 0.00% | 0.00%
NAPS | P/NAPS
0.34 | 0.68
QoQ | YoY
1.85% | 157.84%
NP Margin | ROE
2.64% | 3.01%
F.Y. | Ann. Date
30-Sep-2024 | 22-Nov-2024
Latest Audited Result
Latest Audited Result
31-Dec-2023
Announcement Date
29-Apr-2024
Next Audited Result
31-Dec-2024
Est. Ann. Date
29-Apr-2025
Est. Ann. Due Date
29-Jun-2025
Annual (Unaudited)
Revenue | NP to SH
55,357.000 | 1,558.000
RPS | P/RPS
39.22 Cent | 0.59
EPS | P/E | EY
1.12 Cent | 20.84 | 4.80%
DPS | DY | Payout %
0.00 Cent | 0.00% | 0.00%
NAPS | P/NAPS
0.34 | 0.68
YoY
-40.96%
NP Margin | ROE
2.86% | 3.28%
F.Y. | Ann. Date
31-Dec-2023 | 23-Feb-2024
Annualized Result
Revenue | NP to SH
52,808.000 | -252.000
RPS | P/RPS
37.41 Cent | 0.61
EPS | P/E | EY
-0.15 Cent | -128.84 | -0.78%
DPS | DY | Payout %
-
NAPS | P/NAPS
-
QoQ | YoY
51.35% | -373.91%
NP Margin | ROE
-0.38% | -0.53%
F.Y. | Ann. Date
30-Sep-2024 | 22-Nov-2024
Business Process
| Trailing 4 Quarters | Trailing 8 Quarters | |||
|---|---|---|---|---|
| Available Quarters | 4 Quarters | 8 Quarters | ||
| Continuous Quarters Of Revenue Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Total Positive Profit Years | 3 / 4 | 75.00% | 6 / 8 | 75.00% |
| Continuous Quarters Of Positive Profit | 2 / 4 | 50.00% | 2 / 8 | 25.00% |
| Continuous Quarters Of Profit Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Adjusted EPS Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Total Dividend Years | 0 / 4 | 0.00% | 1 / 8 | 13.00% |
| Continuous Quarters Of Dividend | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Dividend Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Adjusted Dps Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Average ROE | 0.75% | 0.52% | ||
| Average Net Profit Margin | 2.39% | 1.62% | ||
| Last 5 Financial Years | Last 10 Financial Years | |||
|---|---|---|---|---|
| Available Years | 5 Years | 10 Years | ||
| Continuous Quarters Of Revenue Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Total Positive Profit Years | 5 / 5 | 100.00% | 10 / 10 | 100.00% |
| Continuous Quarters Of Positive Profit | 5 / 5 | 100.00% | 10 / 10 | 100.00% |
| Continuous Quarters Of Profit Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Quarters Of Adjusted EPS Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Total Dividend Years | 3 / 5 | 60.00% | 8 / 10 | 80.00% |
| Continuous Quarters Of Dividend | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Quarters Of Dividend Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Quarters Of Adjusted Dps Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Average ROE | 5.67% | 15.48% | ||
| Average Net Profit Margin | 4.37% | 7.95% | ||
Key Result
| T4Q | Annualized | Annual (Unaudited) | Last 10 FY Average | Last 5 FY Average | |
|---|---|---|---|---|---|
| Revenue | 54,721 | 52,808 | 55,357 | 57,094 | 55,567 |
| NP to SH | 1,431 | -252 | 1,558 | 4,566 | 2,549 |
| Dividend | 0 | 0 | 0 | 2,111 | 1,524 |
| Adjusted EPS | 1.01 | -0.15 | 1.12 | 3.23 | 1.79 |
| Adjusted DPS | 0.00 | 0.00 | 0.00 | 1.50 | 1.08 |
NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share
All figures in '000 unless specified.
EPS & DPS's figures in Cent.
Growth
| LQ QoQ | LQ YoY | CQ YoY | LQ vs Average of T4Q | LQ vs Average of T8Q | |
|---|---|---|---|---|---|
| Revenue | -6.93% | -15.46% | -1.71% | -8.74% | -10.55% |
| NP to Owner | -50.58% | 25.49% | -373.91% | -64.22% | -48.44% |
| Dividend | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Adjusted EPS | -55.56% | 14.29% | -237.50% | -68.63% | -54.61% |
| Adjusted DPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year
| T4Q vs LFY | T4Q vs AL5FY | T4Q vs AL10FY | AQR vs LFY | AQR vs AL5FY | AQR vs AL10FY | LFY YoY | LFY vs AL5FY | LFY vs AL10FY | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | -1.15% | -1.52% | -4.16% | -4.60% | -4.97% | -7.51% | -13.39% | -0.38% | -3.04% |
| NP to Owner | -8.15% | -43.86% | -68.66% | -116.17% | -109.89% | -105.52% | -40.96% | -38.88% | -65.88% |
| Dividend | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Adjusted EPS | -9.82% | -43.58% | -68.70% | -113.39% | -108.38% | -104.65% | -36.72% | -37.43% | -65.29% |
| Adjusted DPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year
Discussions
5 people like this. Showing 50 of 295 comments
Hi, I didn't realize that SCC has undergone share split and bonus issue, and it's not reflected in the latest QR, so the calculation of net current asset value is incorrect. I have removed my comment to avoid misleading others.
2017-11-11 23:19
this stock is a dividend stock. If you hope for capital gain you will be disappointed because a majority of the company's earnings are distributed to s/h in form of dividends hence less money for reinvestment. This reinvestment money is essential to fund future growth. Plus the market cap is merely RM76 million, ultra low market cap will not attract institutional funds which are essential to push up the price further. PE of 12.6 is almost reaching the average small market cap index PE. this stock is purely dividen play giving out about 5-6% yield per annum. Anyway this is newbie brief analysis, I dont dig deeper into the company fundamentals so others might have much better insights than I am.
2018-01-17 14:29
this counter still alive? good qr but still no body want it.. so bad..
2018-03-01 12:16
This is a stable dividend stock. If u r buying at this current price,0.5. You are able to gain more than 6.5% on dividend Yield, which is much more better than a FD. Assuming the dividend maintained and increases every semi-annual.
2018-08-10 17:30
Day 59 of Fundamental Daily, YAPSS will be covering SCC Holdings Berhad's fundamental via a short animated video. I hope it helps and please enjoy the video, see ya! #YAPSS #FundamentalDaily #SCCHoldingsBerhad
Click the on the link to find out more: https://youtu.be/rJq51PiFmT0
2019-05-01 22:54
YAPSS Quick Summary and Free 10 Years Financial Data of SCC Holdings Berhad:
https://www.yapss.com/forum/klse-forum/scc-holdings-berhad-scc-0158
2019-12-13 19:37
United Arab Emirates Claims China’s Sinopharm Vaccine Is 100% Effective At Preventing Moderate And Severe Covid-19
TOPLINE The experimental vaccine developed by China National Pharmaceutical Group, also known as Sinopharm, is 86% effective at preventing Covid-19 infection and 100% effective at preventing severe and moderate disease, health officials from the United Arab Emirates announced Wednesday, although with scarce detail provided about the trial.
The UAE health ministry cited an interim analysis of a late-stage clinical trial involving 31,000 volunteers as the source of its information, though neither they nor Sinopharm provided any data from the trial to validate the claims such as how many participants were infected or how many actually received the vaccine.
The ministry said “no serious safety concerns” were observed, though, again, no information on side effects was provided.
The ministry said the announcement is a “significant vote of confidence by the UAE’s health authorities in the safety and efficacy of this vaccine.”
The ministry added that it had officially registered the vaccine at the request of the manufacturer, which it says could eventually lead to the shot’s widespread authorization.
https://www.forbes.com/sites/roberthart/2020/12/09/united-arab-emirates-claims-chinas-sinopharm-vaccine-is-100-effective-at-preventing-moderate-and-severe-covid-19/?sh=2a60fb42595ca
2020-12-10 00:16
This counter has very little ticket : 141 million only. Very easy to goreng if they want to.
2021-04-01 18:10
Average target price : RM 2.69. ; Ticket: 141 million only ; Annual financial reports never lose since 2011 ; Why the present market price so low ?
2021-04-05 07:23
It started to fry. Hopefully keeps frying this coming Monday. Non-stop frying !
2021-07-25 17:10
Post a Comment
Featured Posts
Introducing MY's First IPO Fund for Sophisticated Investors!
New Update. Discover investment communities that resonate with your ideas
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
Apps
Top Articles
2
Mercury Securities Research
3
THE INVESTMENT APPROACH OF CALVIN TAN
SUPERMAX VERSUS TOPGLOVE, KOSSAN & HARTA, Compare & Contrast, By Calvin Tan
4
Koon Yew Yin's Blog
6
7
8
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
prescott2006
cash a lot but those old folks haven't figure out a way to boost their business.
2017-05-30 22:29